Dr Melani discusses results and safety outcomes of the ViPOR trial with venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide to treat R/R and untreated MCL, presented at the 2021 Annual ASH Meeting.

Thomas Slavin, MD, reviews ways to improve polygenic risk scores (PRS) in breast cancer by reducing ancestral bias.

John Mascarenhas, MD, provides insight on the treatment of myelofibrosis patients with the TGF-β 1/3 Inhibitor AVID200 (MPN-RC 118), presented at the 2021 Annual ASH Meeting.

Mark Wildgust, PhD, highlights results from the Phase 3 CASSIOPEIA study of daratumumab as maintenance therapy in first-line MM treatment after stem cell transplant, presented at the 2021 Annual ASH Meeting.

Mark Wildgust, PhD, reviews real-world evidence examining potential healthcare disparities- highlighting patient characteristics, treatment patterns and outcomes for Black and White patients with multiple myeloma who initiated treatment with daratumumab, presented at the 2021 Annual ASH Meeting.

Dr Williams Reviews SunRISe-2 Trial Results for Muscle-Invasive Urothelial Carcinoma by HMP Global

Charu Aggarwal, MD, Penn Medicine, Philadelphia, discusses incorporating plasma-based next-generation sequencing to improve guideline-concordant molecular testing in patients with newly diagnosed metastatic nonsquamous NSCLC.

Tapan M. Kadia, MD, highlights a phase 2 trial on venetoclax plus intensive chemotherapy in patients with newly diagnosed AML or MDS.

Ezzat Elhassadi, MD, Consultant Hematologist, University Hospital, Waterford, Ireland, discusses the impact of a p53 alteration in patients with mantle cell lymphoma (MCL); these data were presented at the EHA2021 Virtual Congress.

Aki Morikawa, MD, PhD, The University of Michigan, discusses assessing risk of brain metastasis in HER2+ breast cancer.